ClinicalTrials.govpublic full text
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
acute myeloid leukemia, aml, favorable risk, azacitidine, decitabine, maintenance therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 899825
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.